#United States #Boston #AI Technology #Xellar #WOOJUNG BIO

Strategic Partnership Between Xellar and WOOJUNG BIO

On January 5, 2026, Xellar Biosystems ("Xellar"), a leading innovator in AI-driven drug discovery technologies, announced a multi-year strategic partnership with WOOJUNG BIO Co., Ltd. ("WOOJUNG BIO"), a biotechnology firm based in South Korea. This collaboration aims to enhance preclinical research capabilities through the integration of AI-powered organ-on-a-chip technologies and extensive translational research expertise.

Advancements in Drug Development

The partnership will focus on combining the strengths of both companies to improve efficiency in drug discovery and development processes. Xellar is known for its revolutionary AI-enabled organ-on-a-chip platforms, which emulate human organs and tissues, allowing for realistic drug testing environments. WOOJUNG BIO will contribute its rich experience in life sciences and translational research, ensuring that the technologies developed are closely aligned with real-world applications.

The collaboration aims to achieve several key objectives:

• - Joint Project Development: By aligning their research and development efforts, both companies will work on innovative projects that push the boundaries of current drug development methods.
• - Technology Integration: The partnership will involve the merging of Xellar's advanced AI and imaging techniques with WOOJUNG BIO's preclinical services, enhancing the quality and reproducibility of research outputs.
• - Co-development of Solutions: Together, they aim to create unique preclinical research solutions that cater to the evolving demands of the healthcare and life sciences sectors.

A Vision for the Future

Xin Xie, CEO of Xellar, expressed his enthusiasm for the collaboration, stating, "This partnership marks a significant milestone in extending the application of our AI and organ-on-a-chip technologies on a global scale. Working with WOOJUNG BIO allows us to bridge the gap between in vitro technologies and actual translational research requirements, ultimately providing increased value to our partners in the life sciences ecosystem."

Heejung Chun, CEO of WOOJUNG BIO, echoed this sentiment, emphasizing the importance of evolving preclinical research methodologies. Chun noted, "As the preclinical landscape shifts toward more human-relevant and alternative research techniques, our strategic collaboration with Xellar aligns perfectly with our mission to lead in the next-generation preclinical market. This partnership will enhance our capabilities and help us develop data-driven approaches that meet our partners' diverse needs."

About Xellar Biosystems

Founded in 2022, Xellar Biosystems specializes in biotechnology innovations that utilize organ-on-a-chip technology combined with AI-driven data analysis. Their mission is to accelerate the drug discovery process by creating authentic 3D human tissue models, making it possible to conduct efficient tests for drug efficacy and safety. Xellar's goal is to streamline drug development, reduce costs, and enhance success rates, ultimately benefiting the biopharmaceutical industry.

About WOOJUNG BIO

WOOJUNG BIO Co., Ltd. offers a comprehensive range of services and solutions designed to support drug discovery and development. They operate as a contract research organization (CRO), providing preclinical services, translational research assistance, and infrastructure for biotech startups. The company's initiatives, such as the WOOJUNG BIO Drug Discovery Cluster, foster an environment conducive to collaboration among various stakeholders in the life sciences sector. This innovative cluster is designed to accelerate biotechnology advancements by integrating laboratory facilities with research capabilities.

Conclusion

The collaboration between Xellar and WOOJUNG BIO represents a dynamic step towards improving the future of drug discovery and development. By leveraging complementary competencies in AI, organ-on-a-chip technologies, and translational research, the partnership is set to facilitate groundbreaking advancements to meet the growing demands of the global healthcare landscape.